These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8320247)

  • 21. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW
    J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic OKT3 used as induction therapy for heart transplantation.
    Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE
    Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
    Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
    Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
    Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B
    J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
    Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
    Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
    Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
    J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.
    Frey DJ; Matas AJ; Gillingham KJ; Canafax D; Payne WD; Dunn DL; Sutherland DE; Najarian JS
    Transplantation; 1992 Jul; 54(1):50-6. PubMed ID: 1631944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithymocyte globulin induction therapy adjusted for immunologic risk after heart transplantation.
    Czer LS; Phan A; Ruzza A; Rafiei M; Setareh-Shenas S; Caceres M; Awad M; Soliman C; Mirocha J; De Robertis M; Kass RM; Trento A
    Transplant Proc; 2013; 45(6):2393-8. PubMed ID: 23953554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antilymphocyte serum, cyclosporine and corticoids, versus OKT3, cyclosporine, and corticoids in kidney transplantation].
    Grino JM; Castelao AM; Seron D; Gonzalez C; Gil-Vernet S; Andres E; Bover J; Mestre M; Alsina J
    Presse Med; 1991 Nov; 20(40):2039-42. PubMed ID: 1837121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
    Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
    J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
    Burk ML; Matuszewski KA
    Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
    Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP
    J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.